0RQO.LSE BoneSupport Holding AB
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- 30.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0RQO.LSE undervalued?
Graham numberThe Graham number of BoneSupport Holding AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BoneSupport Holding AB fundamental analysis
No fundamental analysis for BoneSupport Holding AB yet.
BoneSupport Holding AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BoneSupport Holding AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and …
Full company profileBoneSupport Holding AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BoneSupport Holding AB annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 105M | 129M | 96.6M | 155M | 181M | 213M | 329M | 591M | 899M | 1.17B | 1.45B |
| Gross Profit | 88.3M | 112M | 82.2M | 136M | 162M | 188M | 298M | 541M | 832M | 1.09B | 1.33B |
| Operating Income | -90.4M | -98.5M | -176M | -159M | -97.2M | -85.3M | -67.1M | 22.6M | 147M | 277M | 369M |
| EBITDA | -92.2M | -102M | -173M | -151M | -90.9M | -72.4M | -54.3M | 32.7M | 186M | 288M | 375M |
| Net Income | -110M | -129M | -176M | -161M | -101M | -85.5M | -68.2M | 245M | 134M | 142M | 303M |
| EPS | -4.15 | -3.24 | -3.46 | -3.10 | -1.72 | -1.34 | -1.06 | 3.74 | 2.01 | 2.13 | 4.57 |
| Balance Sheet | |||||||||||
| Total Assets | 189M | 597M | 326M | 196M | 465M | 344M | 372M | 689M | 883M | 1.04B | 1.17B |
| Total Liabilities | 155M | 146M | 47.6M | 72.0M | 66.3M | 78.2M | 103M | 144M | 155M | 169M | 176M |
| Shareholders' Equity | 34.3M | 451M | 279M | 124M | 399M | 266M | 269M | 545M | 727M | 867M | 992M |
| Cash & Short-term Investments | 142M | 533M | 261M | 92.1M | 354M | 206M | 201M | 167M | 227M | 378M | 511M |
| Total Debt | 110M | 98.6M | - | 10.4M | 10.5M | 21.4M | 17.5M | 17.5M | 14.6M | 11.7M | 10.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -81.9M | -108M | -172M | -164M | -100M | -83.4M | -47.0M | -18.3M | 65.8M | 221M | 373M |
| Capital Expenditure | 1.37M | 4.69M | 2.72M | 4.43M | 2.66M | 2.61M | 1.96M | 820K | 1.53M | 2.56M | 2.26M |
| Free Cash Flow | -83.3M | -112M | -174M | -168M | -103M | -86.0M | -48.9M | -19.1M | 64.2M | 219M | 371M |
| Ratios | |||||||||||
| ROE | -321.2% | -28.6% | -63.3% | -129.6% | -25.4% | -32.2% | -25.3% | 44.9% | 18.4% | 16.4% | 30.6% |
| ROA | -58.4% | -21.6% | -54.1% | -82.0% | -21.8% | -24.9% | -18.3% | 35.6% | 15.1% | 13.7% | 26.0% |
| Net Profit Margin | -105.3% | -99.7% | -182.6% | -103.6% | -56.1% | -40.2% | -20.7% | 41.5% | 14.9% | 12.1% | 20.9% |
| Debt to Equity | 3.20x | 0.22x | - | 0.08x | 0.03x | 0.08x | 0.06x | 0.03x | 0.02x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BoneSupport Holding AB dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | SEK 61.6M | 0.96 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BoneSupport Holding AB
- Insiders 8.93%
- Institutions 58.11%
- Public & others 32.96%
- Free float 58.3M
BoneSupport Holding AB company profile
- Company name
- BoneSupport Holding AB
- Ticker
- 0RQO.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 174
- Fiscal year end
- December
- Address
- Scheelevägen 19, Lund, Sweden, 223 70
- Phone
- 46 4 62 86 53 70
- Website
- bonesupport.com
About BoneSupport Holding AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; and CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also provides CERAMENT Bead Tray, an adjunctive local delivery option for surgeons desiring targeted delivery to osseous defects and for dead space management. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.
BoneSupport Holding AB management
9- Mr. Torbjorn SkoldChief Executive Officer · born 1977
- Mr. Håkan JohanssonChief Financial Officer · born 1963
- Mr. Michael Wrang MortensenExecutive Vice President of Global R&D and Operations · born 1975
- Ms. Annelie Aava ViknerExecutive Vice President of Global Marketing · born 1971
- Ms. Helena L. BrandtExecutive Vice President of Human Resources · born 1965
- Dr. Michael Diefenbeck M.D., Ph.D.Executive VP of Medical & Clinical Affairs and Chief Medical Officer · born 1974
- Mr. Fergus MacLeodGM & Executive VP of Commercial Operations of EUROW · born 1970
- Mr. Michael RothGM & Executive VP of Commercial Operations of US · born 1963
- Ms. Anna StegmarkExecutive Vice President of Quality Management & Regulatory Affairs · born 1980